Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) – Stock analysts at SVB Leerink lifted their Q4 2022 earnings per share estimates for Alnylam Pharmaceuticals in a research report issued on Thursday, August 4th. SVB Leerink analyst M. Foroohar now anticipates that the biopharmaceutical company will post earnings per share of $0.24 for the quarter, up from their previous estimate of $0.23. SVB Leerink has a “Market Perform” rating and a $98.00 price target on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($7.85) per share.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last released its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.67). The company had revenue of $224.80 million during the quarter, compared to analysts’ expectations of $256.06 million. Alnylam Pharmaceuticals had a negative return on equity of 204.18% and a negative net margin of 110.91%. The company’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.61) EPS.
Alnylam Pharmaceuticals Stock Down 2.4 %
Shares of NASDAQ ALNY opened at $218.58 on Friday. The company has a debt-to-equity ratio of 3.85, a current ratio of 3.76 and a quick ratio of 3.62. The company has a market cap of $26.24 billion, a P/E ratio of -26.75 and a beta of 0.74. Alnylam Pharmaceuticals has a 1 year low of $117.58 and a 1 year high of $226.00. The firm has a 50-day simple moving average of $145.22 and a two-hundred day simple moving average of $147.90.
Hedge Funds Weigh In On Alnylam Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC grew its holdings in Alnylam Pharmaceuticals by 5.8% in the first quarter. Kestra Advisory Services LLC now owns 1,339 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 74 shares during the last quarter. Signaturefd LLC grew its holdings in Alnylam Pharmaceuticals by 8.1% in the first quarter. Signaturefd LLC now owns 998 shares of the biopharmaceutical company’s stock worth $163,000 after purchasing an additional 75 shares during the last quarter. MUFG Americas Holdings Corp grew its holdings in Alnylam Pharmaceuticals by 5.3% in the fourth quarter. MUFG Americas Holdings Corp now owns 1,755 shares of the biopharmaceutical company’s stock worth $298,000 after purchasing an additional 89 shares during the last quarter. CKW Financial Group grew its holdings in Alnylam Pharmaceuticals by 50.0% in the first quarter. CKW Financial Group now owns 300 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 100 shares during the last quarter. Finally, Commerce Bank grew its holdings in Alnylam Pharmaceuticals by 2.3% in the first quarter. Commerce Bank now owns 4,358 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 100 shares during the last quarter. 92.39% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, EVP Tolga Tanguler sold 1,754 shares of the business’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were sold at an average price of $210.00, for a total value of $368,340.00. Following the completion of the transaction, the executive vice president now owns 3,629 shares of the company’s stock, valued at $762,090. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 5,349 shares of company stock valued at $1,033,073 over the last 90 days. Corporate insiders own 1.40% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- Get a free copy of the StockNews.com research report on Alnylam Pharmaceuticals (ALNY)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.